Carterra[®] LSA Emerging Applications

Noah T. Ditto Carterra Technical Product Manager



Outline

- Antibody Fc Receptor Screening
- Antibody Polyspecificity
- DNA Encoded Libraries
- Targeted Protein Degraders
- Future Applications





High Resolution Fc Receptor Characterization





Kinetics/steady state/potency single chip FcRn workflow

炎



FcRn kinetic and steady state affinities



Drug:FcRn IC₅₀ potency curves

- All values measured in triplicate
- Shown are the higher density surfaces; similar results obtained on lower density surfaces
- Y-scale is response units (RU) normalized to the maximum signal for each replicate



FcRN potency values

- IC₅₀ values are generally comparable across drugs and subclasses
- Pembrolizumab had slightly more potency versus IgG2
- Etanercept showing slightly higher potency across all subclasses

公









● IC₅₀, nM

95% confidence interval

Assessing Antibody Binding to Fc Receptors via HT-SPR

- Demonstrated here with FcRn, but easily expanded to Fc gamma receptors as well
- Inclusion of several densities and controls
- Multiple measures from the same chip: kinetics, steady state affinity, and IC₅₀ potency
- Advantageous as an orthogonal approach to complement other techniques

🔆 carterra

High resolution FcRn IC₅₀ potency measurements using the Carterra[®] LSA[®] platform

Key Takeaways

- Using neonatal Fc receptor (FcRn) as a model system, the versatility of the LSA is demonstrated by measuring binding in three different assay strategies
- Kinetic affinity, steady-state affinity, and IC50 potency values were all obtained using the same ligand array
- · Multiple conditions and controls, all in triplicate, were included due to the high-throughput nature of the LSA
- The capability to conduct potency assays on the LSA highlights new opportunities for leveraging high-throughput surface plasmon resonance (HT-SPR) in drug discovery and development

Materials and Methods

Overview

Potency assays have wide applicability in life science research and development. For therapeutic drug candidates, they are essential across the spectrum of discovery and into development. While many potency assay formats are endpoint in nature, such as enzyme-linked immunosorbent assay (ELISA), there are examples where real-time label-free technologies have been used to determine potency¹. Here we demonstrate how potency assays can be leveraged as part of an overall characterization strategy via HT-SPR using the Carterra LSA. The versatility of the LSA enables researchers to easily adapt to this assay format in conjunction with more commonly used techniques of measuring binding affinity. Additionally, HT-SPR with the LSA presents opportunities to measure up to hundreds of interactions simultaneously, allowing for inclusion of varied assay conditions, controls and replicates not typically feasible with other technologies. Using FcRn as a model system, this application note explores a workflow to characterize kinetic affinity, steady state affinity, and potency in a series. of experiments that can be completed in a single day



APPLICATION NOTE



Preparation of the Coupled Ligand Array

A Carterra LSA instrument was primed into 25 mM MES pH 5.5 (Carterra Part # 3625) + 0.05% Tween-20 (Carterra Part # 3631). An HC30M sensor chip (Carterra Part # 4279) was docked in the instrument and the interaction temperature was set to 25°C. Athens Research immunoglobulins IgG1 (Cat. # 16-16-090707-1), IgG2 (Cat. # 16-16-090707-2), IgG3 (Cat. # 16-16-090707-3), and IgG4 (Cat. # 16-16-090707-4) along with MedChemExpress Adailmumab Cat. # HV-P00108). Penthonlizumab (Cat. # HV-P0012). Tractiziumab (Cat. # HV-P0012).

Antibody Polyspecificity Screening





The case for comprehensive polyspecificity screening

- Much like epitope and affinity, specificity is essential to characterize early in antibody drug discovery
- Empirical polyspecificity screening is the only practical way to assess binding to relevant endogenous biomolecules
- The highly multiplexed nature of the LSA is well designed to screen drug candidates against hundreds of polyspecificity reagents

"For the development of improved workflows to be efficient, they will ideally work across both the **human and research animal** species proteomes, **be rapid**, **cost-effective** to perform, and applicable **early enough in the drug discovery process to maximize their value**. These technologies may be purely experimental, or a combination of **artificial intelligence- driven in silico and in vitro approaches**."

Finley et al. (2021) *Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns*, mAbs, 13:1.



App note: Screening antibodies against array of abundant blood proteins

- Each blood protein arrayed on anti-His coated HC200M in duplicate
- Antibodies injected at low (10nM) and high (100nM) concentrations
- Protein A and antigen used as positive controls
- Regeneration with 10mM glycine pH 1.5



	Anti-RBD mAbs									
	Ab1-10	Ab1-100	Ab2-10	Ab2-100	Ab3-10	Ab3-100	Ab4-10	Ab4-100	Ab5-10	Ab5-100
RBD	0.22	0.41	0.16	0.35	0.35	0.41	0.24	0.35	0.22	0.36
PD1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Protein A	1.56	2.70	1.68	3.74	1.10	2.36	1.01	2.27	1.90	3.20
α-2-macroglobulin	0.02	0.03	0.03	0.04	0.02	0.05	0.03	0.00	0.07	0.05
α-1-acid glycoprotein	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Pepsinogen	0.01	0.01	0.01	0.00	0.01	0.01	0.01	0.00	0.01	0.01
Serum albumin	0.01	0.02	0.00	0.00	0.00	0.01	0.01	0.02	0.00	0.00
Haptoglobin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00
α-1-fetoprotein	0.01	0.01	0.01	0.01	0.00	0.01	0.00	0.00	0.00	0.01
Erythropoietin	0.01	0.01	0.00	0.00	0.01	0.01	0.00	0.01	0.00	0.00
ß-2 microglobulin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Complement component 3	0.01	0.02	0.01	0.01	0.02	0.02	0.01	0.02	0.01	0.01
Fibrinogen 1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00
Mannan binding lectin	0.00	0.00	0.00	0.01	0.00	0.01	0.01	0.01	0.01	0.00
Transferrin	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.02	0.01	0.01
α-1-antitrypsin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Blank	0.18	0.28	0.10	0.08	0.45	0.09	0.20	0.10	0.04	0.02
	Anti-PD1 mAbs									
	Ab6-10	Ab6-100	Ab7-10	Ab7-100	Ab8-10	Ab8-100	Ab9-10	Ab9-100	Ab10-10	Ab10-100
RBD	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PD1	0.35	0.36	0.19	0.33	0.36	0.36	0.36	0.36	0.14	0.35
Protein A	1.13	2.58	0.83	2.03	0.87	2.04	0.57	1.69	0.67	1.85
α-2-macroglobulin	0.02	0.04	0.02	0.04	0.02	0.03	0.03	0.03	0.02	0.03
α-1-acid glycoprotein	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Pepsinogen	0.01	0.01	0.21	0.33	0.01	0.01	0.18	0.29	0.01	0.01
Serum albumin	0.00	0.00	0.07	0.07	0.01	0.00	0.01	0.01	0.01	0.01
Haptoglobin	0.00	0.00	0.15	0.23	0.00	0.00	0.12	0.23	0.00	0.00
α-1-fetoprotein	0.00	0.00	0.10	0.15	0.00	0.00	0.12	0.18	0.00	0.01
Erythropoietin	0.00	0.00	0.01	0.01	0.00	0.01	0.00	0.01	0.00	0.01
B-2 microglobulin	0.00	0.00	0.10	0.12	0.00	0.00	0.11	0.16	0.00	0.00
Complement component 3	0.01	0.02	0.01	0.02	0.01	0.02	0.02	0.02	0.01	0.02
Fibrinogen 1	0.00	0.00	0.22	0.34	0.00	0.00	0.22	0.32	0.00	0.00
Mannan binding lectin	0.00	0.00	0.11	0.14	0.00	0.00	0.08	0.14	0.00	0.00
Transferrin	0.01	0.01	0.01	0.02	0.01	0.00	0.01	0.01	0.01	0.01
α-1-antitrypsin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Blank	0.01	0.01	0.16	0.08	0.12	0.20	31.00	58.00	0.06	0.22

Figure 2. Sequential injections of an anti-PD1 antibody at 10 nM and 100 nM across the protein array.

Enhancing polyspecificity understanding using the LSA

- Screen against hundreds of relevant proteins simultaneously
- Common tag capture strategy makes assay constituents plug and play
- Proteins from both human and preclinical models can be integrated into the same screen

carterra

Profiling antibody polyreactivity and polyspecificity using HT-SPR on the Carterra[®] LSA[®]

Key Takeaways

- Monoclonal antibodies are an important class of therapeutic proteins used to treat a wide range of diseases
- Having a better understanding of the polyreactivity and polyspecificity of potential monoclonal antibody candidates can result in more effective and efficient development of therapeutics
- The LSA, which runs HT-SPR, can be used to fully automate large scale, real-time screening of panels
 of antibodies to gain deep information on their specificity or off-target binding during early development

Introduction

Monoclonal antibodies (mAbs) are one of the most important classes of therapeutic proteins, which are used to treat a wide range of diseases (e.g., oncology, inflammation, and autoimmune diseases). Their use as therapeutics is supported by their ability to bind specifically to their target, have long serum half-lives, and have high tolerability due to the abundance of IgG in the body. Despite these beneficial characteristics, antibodies still regularly fail during therapeutic development. One of the factors causing these failures is linked to polyreactivity and polyspecificity¹⁻⁴. Both terms refer to the ability of an antibody to bind to several targets and in the context of drug development to off-target binding. While polyreactivity can be defined as chemical "stickiness." polyspecificity describes the ability of the antibodies to bind specifically to structurally related epitope on different antigens. Either of these off-target activities can potentially lead to poor pharmacokinetics (PK), potency, bioavailability and/or immunogenicity⁵. Being able to investigate antibody specificity in early discovery is necessary to mitigate costly failure during development phases⁶.

Here, we describe a high-throughput surface plasmon resonance (HT-SPR) assay to profile antibody polyreactivity/polyspecificity. This assay takes advantage of the LSA's ability to monitor binding interactions of an analyte against 384 ligands in an array. A selection of proteins reflecting the human blood biological environment, proteins displaying specific, biophysical properties (highly glycosylated and low PI) and positive controls were included. In addition recombinant antibody target protein, in this case PD-1, was used to understand polyreactivity/polyspecificity. Subsequently, a fully automated assay enabling the characterization of a panel of antibodies in a single run was carried out. The assay automates several steps including the capture of the protein selections,

the injection of the antibodies at two concentrations and the regeneration of the biosensor. The binding levels to the various target proteins were compared to assess the levels of an off-target binding.

APPLICATION NOTE

Materials and Methods Material

The following his-tagged proteins were purchased from Abcam and Sinobiological: Serum albumin (Abcam Cat # ab217817), Fibrinogen (Abcam Cat # ab202200), α-1-anitirypsin (Abcam Cat.# ab276242), Mannan binding lectin (Abcam # ab229367), α-1-acid glycoprotein (Sinobiological Cat.# 16030-H08H), α-1-fetoprotein (Sinobiological Cat.# 12177-H08H), α-2-macroglobulin (Sinobiological Cat.# 10952-H08B), β-2-microglobulin (Sinobiological Cat.# 11976-H08H), Haptoglobin (Sinobiological Cat.# 31382-H08H), Complement component 3 (Sinobiological Cat.# 13182-H08H), Transferrin (Sinobiological Cat.# 1109-H08H), Protein A (Abcam Cat.# ab52953), Pepsinogen (Sinobiological Cat.# 12072-H08H), Erythropoietin (Sinobiological Cat.# 30133-C08H).

Polyreactivity/Polyspecificity Monitoring Assay

For the assay, an HC200M biosensor (Cartera Part # 4287) immobilized with an anti-His antibody (Genscript Cat # A00186) was used. Within the Navigator control software, the Capture Kinetics application was applied to characterize the binding of the antibodies to the immobilized proteins. His-tagged proteins were prepared at 50 nM in HBSTE buffer (Cartera Part # 3630) and captured in duplicate onto the biosensor for 20 min. Protein A and antigen of interest were used as positive controls. Antibodies were diluted to 10 nM and 100 nM in HBSTE buffer and injected over the protein array for 5 min. Finally, surface of the biosensor was regenerated using 3 x 90 s pulses of 10 mM glycine pH 1.5 (Cartera Part # 3639).

Screening of DNA Encoded Libraries





DNA Encoded Library (DEL) Technology



炎

- Key Benefits
 - Rapid screening and identification of hits in a pooled format
 - No structural info required
- Challenges
 - Screening is low-resolution
 - Affinity is unknown
 - Weak binders can be lost



384 DEL compounds arrayed via LNA hybridization

HT-SPR DEL assay metrics

- Max throughput (detailed kinetic affinity)
 - 1,152 DELs/day
 - 5,760 DELs/week
- DEL quantity
 - 44 pmol each
- Target quantity (e.g., 20 kDa protein @ 6uM max conc)
 - 1,152 DELs: 165 ug
 - 5,760 DELs: 495 ug





Representative DEL kinetic screening data

- 1:1 fit model lines in red
- Automatic data flagging in analysis software highlighting low activity (gray) and complex binders (purple)
- 1,152 affinities process in < 10 min

	2 Cmpd_A01_050	1 Cmpd_A01_100	3 Cmpd_A01_200 3 Cmpd_A01_200 40 50 600 900 1200 1500 Time (a)	20 500 500 500 1200 1500 Time (0)	6 Cmpd_A02_050	5 Cmpd_A02_100	40 40 40 40 40 40 40 40 40 40	8 C mpd , A02, 400 40 -20 80 600 900 1200 1800 Time (s)	10 Cmpd_A03_050	9 Cmpd_A03_100 9 Cmpd_A03_100 100 500 500 1200 1500 Time (s)	11 Cmpd A03_200 10 400 50 1200 1500 10 400 50 1200 1500 10 400 50 1200 1500	d_A03_400
	0 40 0 40 0 40 0 40 0 40 0 50 14 Cmpd_A04_050 0 40 0 50 10 120 14 Cmpd_A04_050 0 40 0 50 10 120 10 1900	000 000 1200 1200 1200 1200 1200 1200 1	120 120 120 15 Cmpd A04_200 15 Cmpd A04_200 10 00 000 1200 1500 10 00 000 1200 1500	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	50 50 50 50 50 50 50 50 50 50	000 000 17 Cmpd_A05_100 17 Cmpd_A05_100 000 000 1200 1200 1200 100 000 1200 1200 1200	19 Cmpd_A05_200 19 Cmpd_A05_200 0 0 0 0 0 0 0 0 0 0 0 0	000 20 Cmpd_A05_400 20 Cmpd_A05_400 20 100 100 100 100 100 600 000 1200 1600 Tmm (0)	22 Cmpd_A06_050	21 Cmpd_A06_100 20 20 20 500 600 900 1200 1500 Tmm (0)	8 23 Cmpd A06,200 8 23 Cmpd A06,200 9 24 Cmp 9 25 24 Cmp	d_A06_400
	26 Cmpd_A07_050	25 Crmpd_A07_100	27 Cmpd_A07_200	000 100 200 100 100 100 100 100 100 100	30 Cmpd_A08_050	29 Cmpd_A08_100	100 100 100 100 100 100 100	000 100 32 Cmpd_A08_400 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	34 Cmpd_A09_050	000000000 0000000000000000000000000000	100 100 100 100 100 100 100 100 100 100	Hd_A09_400
	38 Cmpd_A10_050 38 Cmpd_A10_050 40 50 50 600 1200 1500 Tmm 10	37 Cmpd_A10_100 30 cmpd_A10_100 -20 500 600 900 1200 1900 Time 00	39 Cmpd_A10_200	40 Cmpd A10_400	42 Cmpd_A11_050	41.Cmpd_A11_100 40.000 -20 -20 -20 -20 -20 -20 -20 -20 -20	43 Cmpd_A11_200 40 -20 -20 -20 -20 -20 -20 -20 -20 -20 -2	150 150 150 100 100 100 100 100	46 Cmpd, A12,050	45 Cmpd, A12,100 45 Cmpd, A12,100 20 -20 800 600 900 1200 1600 Time ID	47 Cmpd A12,200 48 Cmp 48 Cm	id_Å12_400
9	98 Cmpd_801_050	97 Cmpd_801_100	99 Cmpd_801_200	000 500 500 1200 1600 -20 500 500 1200 1600	500 500 500 500 500 500 500 500	000 000 101 Cmpd_802_100 000 000 -20 500 500 1200 1500 Tm= 10	001 000 000 000 000 000 1000 1000 000 000	100 100 100 100 100 100 100 100 100 100	000 000 106 Cmpd 803.050	105 Cmpd 803,100 105 Cmpd 803,100 105 Cmpd 803,100 105 Cmpd 803,100 105 Cmpd 803,100 105 Cmpd 803,100	0 0 0 0 0 0 0 0 0 0 0 0 0 0	upd_803_400
	110 Cmpd_804_050	00 109 Cmpd_804_100	00 00 00 00 00 00 00 00 00 00	400 112 Crupd 804,400	9 00 0 00 0 00 0 00 0 00 0 00 0 00 0 00 0 1200 1500 0 00 0 1200 1500	0 0 113 Cmpd_805_100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	00 115 Cmpd (905) 200 40 20 -20 500 800 1200 1500 Time (0)	100 100 200 -20 -20 -20 -20 -20 -20 -20 -20 -	8 00 8 40 9 20 -20 -20 500 600 900 1200 1900 Time (0	20 117 Cmpd_806_100	B 40 119 Cmpd 806,200 B 40 120 Cmp 40 10 100 100 100 100 100 100 100 100 10	up.d_806_400
	20 122 Cmpd_807_050	eee 121 Cmpd_807_100	00 123 Cmpd 807 200 0 40 -20 500 600 500 1200 1500 Tm4 50	00 124 Cmpd 807,400 40 20 -20 500 400 800 1200 1500 Tirre 10	400 500 500 500 500 500 500 500	e e e e e e e e e e e e e e e e e e e	127 Cmpd 808 200	e to t28 Cmpd 808,400 t 28 Cmpd 808,400 t 40 t 40	9 00 130 Cmpd 809.050 8 40 20 -20 500 600 500 1200 1500 Tmm (0	129 Cmpd. 809.100	g ⁶⁰ 131 Cmpd 809,200 ⁸⁰ 131 Cmpd 809,200 ⁸⁰ 132 Cm ⁸⁰ 200 100 100 100 ⁸⁰ 200 500 100 100 100 500 500 500 500 500 5	up d. 809_400
	134 Cmpd 810,050	e e e e e e e e e e e e e e e e e e e	900 135 Cmpd,810,200 40 -20 -20 -20 -20 -20 -20 -20 -20 -20 -2	000 136 Cmpd, 810,400	6 50 138 Cmpd 811 050 5 50 500 1200 1200 1500 Time (c)	0 137 Cmpd_811_100	139 Cmpd 811 200 139 Cmpd 811 200 40 500 600 900 1200 1500 Tma (0)	9 00 9 00 9 00 -20 -20 -20 -20 -20 -20 -20 -	300 142 Cmpd 812.050	41 Cmpd.912,100	8 143 Cmpd(812/200) 8 9 144 Cmpd(812/200) 4 5 5 5 5 5 4 7 5 5 7 5 5 7	pd_B12_400
	194 Cmpd_C01_050	193 Cmpd_C01_100 193 Cmpd_C01_100 193 Cmpd_C01_100 193 Cmpd_C01_100 193 Cmpd_C01_100	195 Cmpd_C01_200 195 Cmpd_C01_200 195 Cmpd_C01_200 195 Cmpd_C01_200 195 Cmpd_C01_200 195 Cmpd_C01_200 195 Cmpd_C01_200	100 100 100 100 100 100 100	198 Cmpd_C02_050	197 Cmpd_C02_100	199°Crimpd_C02,200 199°Cr	200 Cmpd+C02,400 5 60 4 20 -20 500 600 500 1200 1500 Tm+ (2)	202 Cmpd_C03_050	201 Cmpd_C03_100 201 Cmpd_C03_100 200 200 200 200 200 Cmpd_C03_100 200 200 Cmpd_C03_100 200 Cmpd_C03_100	0 203 Cmpd C03 200 0 200 500 100 100 200 500 500 100 100 Tm (0)	ipd_C03_400
	206 Cmpd_C04,050	205 Cmpd_C04_100 205 cmpd_C04_100 200 200 200 200 200 200 200	207 Cmpd (C04,200 209	208 Crined C04,400 208 Crined C04,400 209 Control C04,400 209 Crined C04,400 200 C	210 Cmpd_C05_050	209 Cmpd_C05_100	211:Cmpd (C05,200 400 200 -20 500 600 900 1200 1500 Time 60	120 120 120 120 120 120 120 120	214 Cmpd_C06_050	213 Cmpd_C06_100 20 20 20 20 20 20 20 20 20 20 20 20 2	215 Cmpd (C06) 200 40 40 40 40 40 40 40 40 40	epd_CO6_400
	218 Cmpd_C07_050	-20 200 1000 1000 1000 1000 1000 1000 10	219 Cmpd_C07,200 20 20 20 20 500 600 500 1200 1500 Tme i0	220 Cmpd_C07.400	222 Cmpd C08_050	221 Cmpd_C08_100	223 Cmpd_C08,200 40 20 -20 500 600 900 1200 1500 Time (0)	224 Cmpd_C08_400	226 Cmpd_C09_050	225 Cmpd_C09_100 200 200 200 200 200 200 200	227 Cmpd (C0) 200 40 40 40 40 40 40 40 40 40	ep.d. C09, 400 400 800 1200 1500 Time 50
	230 Cmpd_C10_050	229 Cmpd_C10_100	231 Cmpd_C10_200 200 -20 500 600 1000 1000 Tme i0	232 Cmpd_C10_400 232 Cmpd_C10_400 -20 500 600 500 1200 1500 Tm4 50	234 Cmpd C11 050	233 Cmpd_C11_100	235 Cmpd_C11_200 200 -200 500 600 500 1200 1500 Tmm 60	236 Cmpd_C11_400	238 Cmpd_C12_050	237 Cmpd_C12_100 237 cmpd_C12_100 20 20 500 600 900 1200 1500 Tmm i0	239 Cmpd (C12,200 40 40 40 50 500 600 1000 1000 100 7 100 500 600 1000 1000 100 7 100 500 600 7 100 7 1	pd_C12_400
	290 Cmpd_001_050	289 Cmpd [001]100 289 Cmpd [001]100 200 600 900 1200 1500 Tma 10	291 Cmpd [001]200 200 200 200 200 200 200 200 200 200	292 Crupd D01 400 200 500 500 1000 100 500 500 1000	294 Cmpd D02_050	293 Cmpd_D02;100	295 Cmpd D02 200 205 cmpd D02 200 20 20 20 20 20 20 20 20 20 20 20 20	296 Cmpd D02,400 400 -00 500 600 900 1000 1000 Tme I0	298 Cmpd_D03_050	297 Cmpd_D03_100 200 cmpd_003_100 200 cmpd_003_100 200 cmpd_003_100 200 cmpd_003_100	299 Cmpd (003,200 4 0 -10 50 600 100 100 Tm (8) 50 50 600 100 100 -10 50 600 100 100 -10 50 600 100 100	pd_D03_400
	302 Cmpd 004 050	301 Cmpd_D04_100 301 cmpd_D04_100 300 cmpd_D04_100 300 cmpd_D04_100 300 cmpd_D04_100 300 cmpd_D04_100	303 Cmpd_D04_200 303 Cmpd_D04_200 300 Cmpd_D04_200 300 Cmpd_D04_200 300 Cmpd_D04_200 300 Cmpd_D04_200	304 Crinpd D04, 400	306 Cmpd_D05_050	305 Cmpd_D05_100	007 Cmpd [005]200	308 Cmpd D05,400 308 Cmpd D05,400 308 Cmpd D05,400 308 Cmpd D05,400 308 Cmpd D05,400	310 Cmpd_D06_050	309 Cmpd_D06_100	9 0 311 Cmpd D06,200 9 0 312 Cmp 4 0 50 500 120 120 120 1	pd_D06_400

Example of data quality at multiple densities



Kinetic uniformity

22

- 6 DEL compounds tested as 8 replicates each
- 47 kDa protein target injected from 1000 to 0.24 nM
 k_a (M⁻¹s⁻¹)



≤ 10% variation across all on and off-rates



Targeted Protein Degrader (TPD) Characterization





\bigcirc

Therapeutic Value of TPDs

- AKA PROTACS (PROteolysis Targeting Chimeras)
- Harness native intracellular degradation pathways to remove disease-related proteins
- High therapeutic potential where traditional protein-protein inhibitory drug strategies are not appropriate

Warhead targets a specific disease relevant protein E3 ligand recruits a specific E3 ubiquitin ligase



A linker orients the target protein and E3 ligase for catalysis

Typically 700-1000 Da

Binary kinetics example: TPDs targeting VHL and BET proteins

- E3 ligases and target proteins arrayed in triplicate at several densities either covalently or non-covalently
- Multiple compounds injected as titrated series





Kinetics of four TPDs against panel of BET proteins and VHL



炎

Ternary complex evaluation using SIM1, a high-affinity BRD binder



SIM1

trivalent PROTAC mw = 1619 Da $K_D(BRD4) < 1 \text{ nM}$





Ternary specificity: VHL_c + BRD/SIM1





Co-injection of SIM1 then \mbox{VHL}_{c} across multiple BET proteins



VHLc

Time (s)

negative control

Ternary kinetics: VHL_c + BRD/SIM1



Ternary kinetics of VHL_c binding to BRD4(2)/SIM1



Imaide S, et al. *Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity.* Nat Chem Biol. 2021 Nov;17(11):1157-1167.



What the Carterra LSA brings to TPD discovery

Throughput: Screen hundreds of warhead/linker/E3 ligand combinations for both binary and ternary binding/affinity

Specificity: Screen each TPD against up multiple E3 ligases, targets, isoforms etc. in parallel

Flexibility: Multiple assay configurations depending on project needs



Applications on the horizon.....

Aptamers

Membrane proteins including GPCRs



Thank You!

The Carterra Scientific Team

- Judicael Parisot
- Jonathan Popplewell
- Maria McGresham
- Ira Seferovich
- Alyssa Hughes
- Rebecca Rich
- Dan Bedinger
- Camille Troup



